- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01342224
Immunochemoradiotherapy in Patients With Pancreatic Cancer
Exploratory Trial of Immunochemoradiotherapy for Locally Advanced Pancreatic Adenocarcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All study participants receive an initial 4 week course of intra-dermal vaccination with telomerase vaccine (GV1001) and immune adjuvant, granulocyte macrophage colony-stimulating factor (GM-CSF), along with a cycle of gemcitabine chemotherapy. This is followed by concurrent radiation therapy and low-dose intravenous (IV) gemcitabine chemotherapy given twice weekly followed by one additional dose of vaccine.
About 4 weeks (as late as 8 weeks) after chemotherapy and radiation treatment, participants with disease that can be removed by surgery will proceed to surgery. After recovery, immunochemotherapy will resume.
Participants with stable or responsive disease that is not able to be treated with surgery will proceed to immunochemotherapy.
Immunochemotherapy will consist of 2 cycles of telomerase vaccine with GM-CSF along with gemcitabine chemotherapy. Participants with disease that is not able to be treated with surgery, or that has worsened following immunochemoradiotherapy phase of treatment may continue on study with transition to immunochemotherapy phase of treatment. Tadalafil will be administered orally on a daily basis from start of therapy (Day 1) through completion of therapy with doses held only when required in the immediate perioperative period in patients who proceed to surgery.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Health & Services
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Pancreatic adenocarcinoma proven by biopsy or cytology Locally advanced, unresectable disease with absence of distant metastatic disease. The presence of non-regional retroperitoneal or abdominal adenopathy is acceptable for inclusion.
OR
Borderline resectable pancreatic adenocarcinoma (any of the following):
- Tumor abutment or encasement of a short segment of hepatic artery (without evidence of tumor extension to the celiac artery) that is amenable to resection and reconstruction
- Tumor abutment of the superior mesenteric artery involving 180 degrees or less of the circumference of the artery and without encasement
- Impingement or narrowing of the superior mesenteric vein/portal vein or short-segment (< 2 cm) occlusion of the superior mesenteric vein, portal vein, or their confluence with a suitable option for vascular reconstruction
- Eastern Cooperative Oncology Group(ECOG)Performance Status 0 or 1
- Ability to give informed consent and comply with the protocol
- Women of childbearing potential must have a negative pregnancy test and must avoid becoming pregnant while on treatment. Men must avoid fathering a child while on treatment.
- Patients with a history of psychiatric illness must be judged able to understand fully the investigational nature of the study and the risks associated with the therapy.
Exclusion Criteria:
- Age < 18 years
- History of other malignancy in the past 2 years except carcinoma in situ of the cervix or bladder, or non-melanomatous skin cancer
- Previous chemotherapy or radiation therapy for pancreatic cancer or previous radiation therapy to the target field
- Clinically active autoimmune disease or active infection
- History of heart attack (within 90 days) or stroke (within 6 months), or presence of hypertension requiring change in blood pressure medications in the last 4 weeks, hypotension, uncontrolled arrhythmias, heart failure (New York Heart Association (NYHA) Functional Classification ≥ Class 2 in last 6 months), unstable angina or angina occurring during sexual activity.
- Use of "nitrates" or nitroglycerin.
- History of hereditary degenerative retinal disorders including retinitis pigmentosa.
- Chronic systemic corticosteroid use at supra-physiologic doses (prednisone > 10 mg a day or equivalent)
- Use of recreational drugs called "poppers" like amyl nitrite and butyl nitrite.
Laboratory values (performed within 14 days prior to enrollment) as follows:
- Neutrophil count < 1500 cells/µL
- Hemoglobin < 9 gm/dL (patients may be transfused to establish eligibility)
- Platelet count < 100,000 cells/µL
- Significant coagulopathy (INR > 1.5)
- Significant liver or renal dysfunction
- Other medical or psychiatric conditions that in the opinion of the Principal Investigator would preclude safe participation in protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: tadalafil and vaccination
Participants receive a 4-week course of vaccination with telomerase vaccine and GM-CSF by injection, along with a cycle of gemcitabine chemotherapy (IV).
This is followed by radiation and gemcitabine given twice weekly then by another dose of vaccine.
|
Participants receive a 4-week course of vaccination with telomerase vaccine and GM-CSF by injection, along with a cycle of gemcitabine chemotherapy (IV).
This is followed by radiation and gemcitabine given twice weekly then by another dose of vaccine.
Four weeks after completion of chemotherapy and radiation, participants able to have surgical treatment will have surgery followed by vaccination and chemotherapy.
Participants with stable or responsive disease that cannot be treated by surgery will have vaccination and chemotherapy with 2 cycles of telomerase vaccine with GM-CSF along with gemcitabine.
Participants with unresectable and progressive disease after administration of vaccine, chemotherapy and radiation treatment may transition to vaccination and chemotherapy treatment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: 180 Days
|
Adverse events will be graded no less than weekly for the first 180 days.
Post-treatment long-term follow-up will occur every 12 weeks beyond day 180 for 6 visits and then every 24 weeks thereafter until progressive disease, withdrawal from study or death.
For this pilot study, adverse events and efficacy measures will be personally reviewed by the principal investigator.
Both hematologic and non-hematologic toxicity will be anticipated.
In conjunction with the IRB, stopping the trial will be among possible measures taken if undue toxicity or inadequate outcomes are observed.
|
180 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune Response
Time Frame: 18 months
|
In patients having surgery: Tumor tissue obtained at the time of surgery will be examined to determine the degree of macrophage and T cell infiltration.
In all patients: Multiparameter flow cytometry will determine the frequency of circulating telomerase-specific memory CD8+ T cells in blood samples obtained pre- and post- treatment.
Accrual is anticipate to last 10-12 months, so post treatment samples from the last patient enrolled would be available for analysis approximately 18 months after the first patient enrolled.
|
18 months
|
Tumor Response
Time Frame: 180 days
|
Response and progression will be evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee.
Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST criteria.
Tumor measurements are made 4 times during the study, the last at 180 days after study enrollment.
|
180 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Todd Crocenzi, MD, Providence Health & Services
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Anti-Infective Agents
- Urological Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Phosphodiesterase Inhibitors
- Phosphodiesterase 5 Inhibitors
- Gemcitabine
- Tadalafil
- Sargramostim
Other Study ID Numbers
- PHS 10-141B
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Pancreatic Adenocarcinoma
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingPancreas Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic AdenocarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterArcus Biosciences, Inc.SuspendedBorderline Resectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Georgetown UniversityERYtech PharmaActive, not recruitingMetastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
TriSalus Life Sciences, Inc.RecruitingLocally Advanced Pancreatic AdenocarcinomaUnited States
-
Fuda Cancer Hospital, GuangzhouCompletedLocally Advanced Pancreatic AdenocarcinomaChina
-
National Cancer Institute (NCI)RecruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Locally Advanced Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Unresectable Pancreatic AdenocarcinomaUnited States
-
Impact Biotech LtdImpact biotech Ltd.Not yet recruitingLocally Advanced Unresectable Pancreatic Adenocarcinoma
-
OncoSil Medical LimitedNot yet recruitingLocally Advanced Pancreatic Adenocarcinoma
-
UMC UtrechtRadboud University Medical Center; Catharina Ziekenhuis Eindhoven; Amsterdam... and other collaboratorsNot yet recruitingLocally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy (LAPSTAR)Locally Advanced Pancreatic AdenocarcinomaNetherlands
-
Michael ChuongNovoCure Ltd.RecruitingPancreas Cancer | Locally Advanced Pancreatic Adenocarcinoma | Locally AdvancedUnited States
Clinical Trials on tadalafil and vaccination
-
University of OxfordCompleted
-
Castilla-La Mancha Health ServiceCompleted
-
Radboud University Medical CenterCompletedProstatic Neoplasms | Immunotherapy | Vaccines | Dendritic CellsNetherlands
-
Jesús Moreno FernándezCastilla-La Mancha Health Service; University of Castilla-La ManchaCompletedType 1 Diabetes MellitusSpain
-
Children's Cancer Group, ChinaShanghai Pudong District Center for Disease Control and PreventionRecruitingHematologic Malignancy | Solid Tumor, Childhood | VaccinationChina
-
Serge ThalCompletedSARS-CoV2 Infection | Tolerance | Immunisation Reaction | Antibody HypersensitivityGermany
-
Radboud University Medical CenterCompleted
-
Queen's UniversityMerck Canada Inc.Not yet recruiting
-
German Cancer Research CenterUniversity Hospital Heidelberg; National Center for Tumor Diseases, HeidelbergRecruiting
-
University of OxfordCompleted